A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s)

This study is testing a new experimental drug called RO7673396 to see how it affects advanced solid tumors that have a specific genetic change called a 'RAS mutation.' Researchers are looking to find the safest dose and to see if this treatment can help slow down or shrink these tumors.

This trial is for adults with advanced solid tumors that have spread or returned and cannot be cured. You must have measurable tumors, be able to perform daily light activities, and have healthy enough liver and kidney function to safely receive the medication.

You will receive the study drug as part of a research process designed to find the best dose and check for potential side effects. The study is split into two stages: first finding the right dose, and then seeing how well that dose works to fight the cancer.

The study is currently recruiting patients at locations in Duarte, California; Aurora, Colorado; and New Haven, Connecticut. If you are interested, your doctor can help you determine if this study is the right fit for your situation.